Clinical and Translational Oncology

, Volume 13, Issue 11, pp 826–830

Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome

  • Erdem Cubukcu
  • Omer Fatıh Olmez
  • Ozlem Saraydaroglu
  • Unsal Akcalı
  • Ozkan Kanat
  • Ender Kurt
  • Turkkan Evrensel
  • Osman Manavoglu
Research Articles

DOI: 10.1007/s12094-011-0741-7

Cite this article as:
Cubukcu, E., Olmez, O.F., Saraydaroglu, O. et al. Clin Transl Oncol (2011) 13: 826. doi:10.1007/s12094-011-0741-7
  • 68 Views

Abstract

Introduction

The identification of novel prognostic markers may help to better assess survival probability in different subgroups of patients with non-small-cell lung cancer (NSCLC) and to tailor treatment according to the molecular profile of the tumour.

Aim

We sought to examine whether the immunohistochemical expression of excision repair cross-complementing 1 (ERCC1), an essential component of the nucleotide excision repair pathway, may predict prognosis in NSCLC.

Material and method

Formalin-fixed paraffin-embedded tumour samples from 44 Turkish patients with NSCLC treated by adjuvant platinum-based chemotherapy were included in the study. Immunohistochemical expression levels of ERCC1 were correlated with clinical outcomes by Kaplan-Meier curves and multivariable Cox proportional hazards regression analysis.

Results

A total of 29 patients had ERCC1-negative tumours while 15 had ERCC1-positive tumours. The mean progression-free survival (PFS) was significantly lower in patients with ERCC1-positive tumours (13±2 months) than in those with ERCC1-negative tumours (27±5 months, p<0.05). Similarly, the mean overall survival (OS) was significantly lower in patients with ERCC1-positive tumours (20±3 months) than in those with ERCC1-negative tumours (33±5 months, p<0.05). After allowance for potential confounders, Cox regression analysis demonstrated that ERCC1 expression was significantly associated with both PFS and OS (both p<0.05).

Conclusion

This study provides support for the prognostic value of ERCC1 immunohistochemical expression in patients with NSCLC treated by adjuvant platinum-based chemotherapy. If independently confirmed, these findings may improve prognostic stratification in this group of patients.

Keywords

Non-small-cell lung cancerExcision repair cross-complementing 1ImmunohistochemistryPrognosis

Copyright information

© Feseo 2011

Authors and Affiliations

  • Erdem Cubukcu
    • 1
  • Omer Fatıh Olmez
    • 1
  • Ozlem Saraydaroglu
    • 2
  • Unsal Akcalı
    • 3
  • Ozkan Kanat
    • 1
  • Ender Kurt
    • 1
  • Turkkan Evrensel
    • 1
  • Osman Manavoglu
    • 1
  1. 1.Department of OncologyUludag University Medical SchoolBursaTurkey
  2. 2.Department of PathologyUludag University Medical SchoolBursaTurkey
  3. 3.Department of Internal MedicineUludag University Medical SchoolBursaTurkey